A clinical evaluation of glibenclamide (HB 419, "Daonil") a new antidiabetic sulphonylurea.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000428:Alcohol Drinking; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005260:Female; D005951:Glucose Tolerance Test; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects; D013453:Sulfonylurea Compounds / Q000009:adverse effects; D014044:Tolbutamide / Q000627:therapeutic use
D007328:Insulin; D011743:Pyrimidines; D013453:Sulfonylurea Compounds; D014044:Tolbutamide; D005905:Glyburide